Monday, 26 October 2026European Markets

NEW SOURCES ENERGY Stock Went Up By Over 23% So Far Today

Loading stream...

(VIANEWS) - Shares of NEW SOURCES ENERGY (AEX-Index: NSE.AS) rose by a staggering 23.08% to €0.02 at 14:09 EST on Tuesday, after three sequential sessions in a row of losses. AEX-Index is sliding 0.02% to €773.28, following the last session's downward trend. This seems, as yet, a somewhat negative trend trading session today.

About NEW SOURCES ENERGY

New Sources Energy N.V. develops, operates, exploits, and invests in projects that generates electricity using renewable energy sources. The company was formerly known as Management Share NV and changed its name to New Sources Energy N.V. in July 2011. New Sources Energy N.V. is headquartered in Amersfoort, the Netherlands.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NEW SOURCES ENERGY's stock is considered to be overbought (>=80).

Volatility

NEW SOURCES ENERGY's last week, last month's, and last quarter's current intraday variation average was a negative 19.05%, a negative 4.98%, and a positive 10.64%.

NEW SOURCES ENERGY's highest amplitude of average volatility was 19.05% (last week), 8.52% (last month), and 10.64% (last quarter).

Volume

Today's last reported volume for NEW SOURCES ENERGY is 28550 which is 70.01% below its average volume of 95213.

More news about NEW SOURCES ENERGY (NSE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com